VentiRx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of medicines for the treatment of cancer, and respiratory and autoimmune diseases. The company focuses on the development of small molecule product candidates targeting toll-like receptor 8 (TLR8) agonists and antagonists. Its product pipeline comprises VTX-2337, a small molecule TLR8 agonist that stimulates myeloid dendritic cells and monocytes, and enhances natural killer cell responses for the treatment of solid tumors, ovarian and breast cancers, and NHL and SCHN; VTX-1463, a stand alone agent for the treatment of seasonal and perennial allergies; TLR8 antagonists for the treatment of autoimmune diseases; and multiple compounds that are treated as vaccine adjuvants. The company has a strategic agreement/collaboration with Celgene Corporation. VentiRx Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Seattle, Washington with operations in San Diego.

from http://www.ventirx.com/about/index.html

Patents 141show all

  • 53
    A61K - Preparations for medical, dental, or toilet purposes
  • 40
    C07D - Heterocyclic compounds
  • 15
    B82Y - Specific uses or applications of nanostructures
  • 14
    C07K - Peptides

Clinical Trials 1show all

1Phase 1/Phase 2

SEC Filings show all


4
D

Contact Information

1191 Second Avenue Suite 1105
Seattle, WA 98101
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$104,502,51411-502014-09-23Operating

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2014-09-23$50,602,514Series BARCH Venture Partners, Frazier Healthcare Partners, Domain Associates, MedImmune Ventures, Celgene
2006-01-01$2,300,000Seed
2010-01-13$25,000,000Series AMedImmune VenturesARCH Venture Partners, Frazier Healthcare Partners, Domain Associates
2007-03-06$26,600,000Series AFrazier Healthcare PartnersDomain Associates, ARCH Venture Partners

SEC Form D Funding Events

DateOfferedSoldType
2014-09-30$15,000,000$15,000,000Equity, Option to Acquire, Security to be Acquired
2014-09-23$53,102,414$50,602,514Equity
2012-03-08$25,000,002$18,750,001Equity
2007-03-22Unknown Unknown Other (Paper Filing)

Key Executives

  • Robert M. Hershberg, M.D., Ph.D.
    Executive Officer, Director
  • Patrick Heron
    Director
  • Nicole Vitullo
    Director
  • Steven Gillis, Ph.D.
    Director
  • Elliot Grossbard, M.D.
    Director
  • Atul Saran
    Director
  • Kent Snyder
    Director
  • Ron Laufer
    Director
  • Kathleen Fanning
    Executive Officer